BioCentury | Jun 25, 2009
Strategy

Science for export

...France $2.9M Neurokin S.A. Cyclin-dependent kinase inhibitors for stroke and epilepsy 2003 Marseille, France $625K Pharmaxon S.A....
BioCentury | Jun 4, 2007
Company News

Pharmaxon, Schafer-N ApS, French National Center for Scientific Research, University of Aix-Marseille II, University Medical Center Hamburg-Eppendorf deal

...number of preclinical polysialic acid (PSA) mimetic peptides from Schafer-N, the center and the universities. Pharmaxon...
...activators to treat acute spinal cord injury and neurodegenerative diseases. Financial terms were not disclosed. Pharmaxon S.A....
BioCentury | Jan 8, 2007
Emerging Company Profile

Pharmaxon: Normalizing neurons

...that several CNS indications are characterized at least in part by abnormal movement of neurons, Pharmaxon S.A....
...molecules and is thought to play an important role in preventing the re-growth of neurons. Pharmaxon...
...becomes permeable - and this is the period when the glial scarring appears, Deschaseaux said. Pharmaxon...
BioCentury | Jan 8, 2007
Emerging Company Profile

Corporate Profile

Pharmaxon S.A. Marseille, France Technology: Modulation of adhesion molecules in CNS Disease focus: Neurology Clinical status: Preclinical Founded: 2004 by Pascal Deschaseaux, Genevive Rougon and Jean-Christien Norreel University collaborators: French National Cancer Institute (INCa); Centre...
Items per page:
1 - 4 of 4
BioCentury | Jun 25, 2009
Strategy

Science for export

...France $2.9M Neurokin S.A. Cyclin-dependent kinase inhibitors for stroke and epilepsy 2003 Marseille, France $625K Pharmaxon S.A....
BioCentury | Jun 4, 2007
Company News

Pharmaxon, Schafer-N ApS, French National Center for Scientific Research, University of Aix-Marseille II, University Medical Center Hamburg-Eppendorf deal

...number of preclinical polysialic acid (PSA) mimetic peptides from Schafer-N, the center and the universities. Pharmaxon...
...activators to treat acute spinal cord injury and neurodegenerative diseases. Financial terms were not disclosed. Pharmaxon S.A....
BioCentury | Jan 8, 2007
Emerging Company Profile

Pharmaxon: Normalizing neurons

...that several CNS indications are characterized at least in part by abnormal movement of neurons, Pharmaxon S.A....
...molecules and is thought to play an important role in preventing the re-growth of neurons. Pharmaxon...
...becomes permeable - and this is the period when the glial scarring appears, Deschaseaux said. Pharmaxon...
BioCentury | Jan 8, 2007
Emerging Company Profile

Corporate Profile

Pharmaxon S.A. Marseille, France Technology: Modulation of adhesion molecules in CNS Disease focus: Neurology Clinical status: Preclinical Founded: 2004 by Pascal Deschaseaux, Genevive Rougon and Jean-Christien Norreel University collaborators: French National Cancer Institute (INCa); Centre...
Items per page:
1 - 4 of 4